Two novel biosimilars approved in EU and US
The first omalizumab biosimilar in allergic diseases is approved by…
The first omalizumab biosimilar in allergic diseases is approved by the European Commission and the US Food and Drug Administration (FDA) has authorised the fifty third biosimilar in the US.